HAVCR1 Affects the MEK/ERK Pathway in Gastric Adenocarcinomas and Influences Tumor Progression and Patient Outcome

Table 2

Univariate and multivariate analysis of clinic pathologic factors for overall survival in GAC patients.

Variables	Univariate analysis			Multivariate analysis
	value	HR	95% CI	value	HR	95% CI
HAVCR1 expression (high/low)	0.013	1.580	1.101-2.265	0.008	1.633	1.134-2.353
Clinical stage (I+II/III+IV)	0.001	1.883	1.292-2.745	0.092	1.534	0.933-2.523
Pathologic-T (T1+T2/T3+T4)	0.064	1.529	0.975-2.398
Pathologic-M (M0/M1)	0.126	1.659	0.868-3.173
Pathologic-N (N0/N1+N2+N3)	0.005	1.873	1.207-2.906	0.225	1.431	0.802-2.553
Age (<60/≥60)	0.011	1.697	1.128-2.551	0.002	1.954	1.292-2.955
Gender (female/male)	0.083	1.405	0.956-2.065
Grade (G1+G2/G3)	0.124	1.340	0.923-1.946

HR: hazard ratio; CI: confidence interval. Significant correlation.